{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:50:52Z","timestamp":1785484252572,"version":"3.56.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"crossref","award":["2014-3-054"],"award-info":[{"award-number":["2014-3-054"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"crossref","award":["2019-4-025"],"award-info":[{"award-number":["2019-4-025"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Glucocorticoids (GCs), especially low-dose GCs, are commonly prescribed for rheumatoid arthritis (RA), although the risk\/benefit ratio is controversial. A randomized, double-blind clinical trial was performed to evaluate the efficacy and safety of low-dose oral GCs combined with methotrexate (MTX) and hydroxychloroquine (HCQ) in early RA (ERA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eighty untreated ERA patients were randomized into the trial (GCs + MTX + HCQ) and control (placebo + MTX + HCQ) groups, for 1-year treatment. Therapeutic evaluation indices were American College of Rheumatology (ACR) 20 of ACR, disease activity score (DAS) 28- erythrocyte sedimentation rate (ESR), visual analog scale scores, joint function, health assessment questionnaire-disability index score, morning stiffness duration, C-reaction protein and ESR. The clinical indicators were evaluated pre-treatment and at 1st, 3th, 6th and 12th month of treatment. The MRI data of single joint (ie, the most swollen joint) for each patient were acquired with a revised OMERACT RAMRIS Scoring System before and after treatment. The correlation analysis was adopted to confirm whether the efficacy of GC treatment is related to the time of RA onset. The side effects (eg, gastrointestinal reactions, liver dysfunction, upper respiratory tract infection, leukocyte reduction) were also monitored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>At 1st month, 55% and 20% cases in the experimental and control groups achieved ACR20 response, respectively, indicating a significant difference (<jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>\n                                    2\n                                 <\/jats:sup>\u200a=\u200a16.157, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). This trend continued until 6th month. At 12th month, the number of patients achieved ACR20 response was similar in both groups. At 1st to 6th month, DAS28- ESR scores in the experimental group were significantly lower than control values (all <jats:italic toggle=\"yes\">p<\/jats:italic>\u200a&lt;\u200a.05). The experimental group showed improved inflammation, quality of life and radiological symptoms. Bone erosion remained unchanged in the experimental group, while worsening in control group. Correlation coefficients between RA duration and DAS28-ESR score were 0.496, 0.464, 0.509, and 0.550 at 1st, 3th, 6th, and 12th month, respectively. No differences were found in adverse events between the 2 groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Low-dose GCs combined with MTX and HCQ significantly achieves disease remission indexed by ACR20 and DAS28-ESR, and improves clinical and radiological outcomes in ERA patients at the early stage, with superiority over placebo + MTX + HCQ, without enhancing adverse reactions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020824","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T16:38:20Z","timestamp":1593448700000},"page":"e20824","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis"],"prefix":"10.1097","volume":"99","author":[{"given":"Li","family":"Hua","sequence":"first","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jinhua Municipal Central Hospital, Jinhua Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"R1-20240214","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/ker370","article-title":"Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing","volume":"51","author":"Li","year":"2012","journal-title":"Rheumatology"},{"key":"R2-20240214","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4314\/ejhs.v28i1.13","article-title":"The difficult rheumatology diagnosis","volume":"28","author":"Devaraj","year":"2018","journal-title":"Ethiop J Health Sci"},{"key":"R3-20240214","first-page":"957","article-title":"The Atypical presentation of rheumatoid arthritis in an elderly woman: a case report","volume":"29","author":"Devaraj","year":"2019","journal-title":"Ethiop J Health Sci"},{"key":"R4-20240214","first-page":"1792","article-title":"Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)","volume":"22","author":"van der Heijde","year":"1995","journal-title":"J Rheumatol"},{"key":"R5-20240214","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/ard.62.7.611","article-title":"Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis","volume":"62","author":"Lindqvist","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R6-20240214","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention","volume":"46","author":"Landewe","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R7-20240214","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.10135","article-title":"Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis","volume":"46","author":"Mottonen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R8-20240214","first-page":"623","article-title":"Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study","volume":"27","author":"Tsakonas","year":"2000","journal-title":"J Rheumatol"},{"key":"R9-20240214","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.10092","article-title":"Treating rheumatoid arthritis early: a window of opportunity?","volume":"46","author":"O\u2019Dell","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-20240214","first-page":"565","article-title":"Remodeling the pyramid--a concept whose time has come","volume":"16","author":"Wilske","year":"1989","journal-title":"J Rheumatol"},{"key":"R11-20240214","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","article-title":"Understanding the window of opportunity concept in early rheumatoid arthritis","volume":"48","author":"Boers","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R12-20240214","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/ard.2009.127332","article-title":"Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis","volume":"69","author":"Gorter","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R13-20240214","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/rheumatology\/keu135","article-title":"Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis","volume":"53","author":"Kavanaugh","year":"2014","journal-title":"Rheumatology"},{"key":"R14-20240214","first-page":"CD006356","article-title":"Effects of glucocorticoids on radiological progression in rheumatoid arthritis","author":"Kirwan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20240214","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-156-5-201203060-00014","article-title":"Combination therapy including glucocorticoids: the new gold standard for early treatment in rheumatoid arthritis?","volume":"156","author":"Kirwan","year":"2012","journal-title":"Ann Intern Med"},{"key":"R16-20240214","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"R17-20240214","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/art.21298","article-title":"Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial","volume":"52","author":"Svensson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R18-20240214","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R19-20240214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R20-20240214","first-page":"383","article-title":"Clinical observation on the curative effect of low-dose corticosteroids combined with methotrexate in the treatment of early rheumatoid arthritis","volume":"24","author":"Hua","year":"2014","journal-title":"Zhejiang J Integr Tradit Chin West Med"},{"key":"R21-20240214","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R22-20240214","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/acr.20393","article-title":"Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients","volume":"63","author":"Morris","year":"2011","journal-title":"Arthritis Care Res"},{"key":"R23-20240214","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3899\/jrheum.090994","article-title":"Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus","volume":"37","author":"Penn","year":"2010","journal-title":"J Rheumatol"},{"key":"R24-20240214","first-page":"102","article-title":"Factors associated with low bone mineral density in female patients with systemic lupus erythematosus","volume":"28","author":"Lakshminarayanan","year":"2001","journal-title":"J Rheumatol"},{"key":"R25-20240214","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"R26-20240214","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"R27-20240214","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF02032335","article-title":"Measurement of disability in Dutch rheumatoid arthritis patients","volume":"3","author":"Siegert","year":"1984","journal-title":"Clin Rheumatol"},{"key":"R28-20240214","first-page":"110","article-title":"Clinical value of modified MRI scoring system in evaluating the activity of rheumatoid arthritis","volume":"1","author":"Liu","year":"2010","journal-title":"Chinese Journal of Magnetic Resonance Imaging"},{"issue":"(Suppl 1)","key":"R29-20240214","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1136\/ard.2004.031773","article-title":"An introduction to the EULAR\u2013OMERACT rheumatoid arthritis MRI reference image atlas","volume":"64","author":"\u00d8stergaard","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R30-20240214","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/ard.2004.031815","article-title":"The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the metacarpophalangeal joints","volume":"64","author":"Conaghan","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R31-20240214","doi-asserted-by":"crossref","first-page":"i23","DOI":"10.1136\/ard.2004.031823","article-title":"The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint","volume":"64","author":"Ejbjerg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R32-20240214","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/art.21421","article-title":"Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial","volume":"52","author":"Wassenberg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R33-20240214","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar3838","article-title":"Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study","volume":"14","author":"Montecucco","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R34-20240214","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N Engl J Med"},{"key":"R35-20240214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-136-1-200201010-00006","article-title":"Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial","volume":"136","author":"van Everdingen","year":"2002","journal-title":"Ann Intern Med"},{"key":"R36-20240214","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R37-20240214","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/ard.2009.114579","article-title":"Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R38-20240214","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/ard.61.4.290","article-title":"Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide","volume":"61","author":"Emery","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"R39-20240214","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199405123301908","article-title":"Second-line drug therapy for rheumatoid arthritis","volume":"330","author":"Cash","year":"1994","journal-title":"N Engl J Med"},{"key":"R40-20240214","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","article-title":"Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R41-20240214","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R42-20240214","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R43-20240214","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","article-title":"Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort","volume":"76","author":"Roubille","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R44-20240214","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:06:57Z","timestamp":1707926817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020824"}},"subtitle":["A single-center, randomized, double-blind clinical trial"],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":44,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020824","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}